Ikuo Yamamiya

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal et al. · Annals of Oncology · 2020 · 151 citations · Full text

Medicine, Oncology, Pharmacology +14

In vivo detection of free radicals induced by diethylnitrosamine in rat liver tissue

Ken‐ichi Yamada, Ikuo Yamamiya, Hideo Utsumi · Free Radical Biology and Medicine · 2006 · 76 citations

Pharmacy, Biochemistry, Toxicology +8

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa et al. · ACS Medicinal Chemistry Letters · 2023 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers

Eri Takeshita, Hirofumi Komaki, Hisateru Tachimori et al. · Brain and Development · 2018 · 23 citations

Life Sciences, Biochemistry, Molecular Biology +7

Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity

Ikuo Yamamiya, Kunihiro Yoshisue, Yuji Ishii et al. · Drug Metabolism and Disposition · 2014 · 16 citations

Medicine, Biochemistry, Pharmacology +17